NCI SBIR provides
funding, mentoring & networking assistance
for small businesses with next-generation cancer technologies.
Due to the potential impact of the declared public health emergency caused by COVID-19, the NIH has issued multiple guide notices, incluing notice on late applications. If your business is affected by COVID-19, check the list of available measures on our Notices Page.
For updates on NCI extramural funding activities, please check NCI Director Dr. Norman E. Sharpless' post on the NCI Bottom Line blog.
The SBIR & STTR Programs are one of the largest sources of early stage technology financing in the United States. We welcome entrepreneurs and small business leaders to this website to explore grant and contract funding opportunities.
Learn how NCI SBIR & STTR Programs have helped small businesses with funding awards that help advance cancer research.
AntiCancer, the San Diego-based biotechnology company, was awarded Phase I and II SBIR grants and contracts that have led to the commercialization of three cancer research tools: MetaMouse®, AngioMouse®, and OncoBrite®.
Developed LuViva, a non-invasive medical device designed to instantly detect cervical disease in a point-of-care setting with a $2.5 million Bridge Award.
The NCI SBIR Development Center is issuing a Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). This supplement is open to current SBIR- and STTR-funded projects. For more information, visit the award page.
Due to the potential impact of the declared public health emergency caused by the 2019 Novel Coronavirus (COVID-19), the NIH has issued multiple guide notices, incluing notice on late applications. If your business is affected by COVID-19, check the list of available measures on our Notices Page.
New opportunities for current Phase I SBIR companies! Get supplement funding to move your project to the next stage! Check the new Notice of Special Interest today.
You can now find application deadlines and cohort dates for I-Corps at NIH 2020 cohorts! Check our I-Corps at NIH page for more information.
Recent legislation has re-instated the SBIR Direct-to-Phase II provision. Applicants can now apply for Direct-to-Phase II for SBIR Omnibus Solicitation, as well as targeted funding opportunities. For more information, please check Guide Notices NOT-OD-19-019 (Omnibus), NOT-CA-19-002 (IMAT), and NOT-CA-19-003 (Low Resource Settings)
NIH will no longer accept late applications due to delays in SAM registration or renewal, as GSA is no longer requiring entities to have an approved Entity Administrator notarized letter on file before their registration is activated. For the full announcement, please refer to NOT-OD-18-215.
System for Award Management (SAM) registration is FREE. You can always get free system and technical help through our supporting Federal Service Desk. In addition, Procurement Technical Assistance Centers (PTACs) can provide free help with your SAM Registration – and other government contracting issues. Read more: HERE and HERE.